Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK science & innovation head resigns:

This article was originally published in Clinica

Executive Summary

On the eve of a UK review of science and innovation policy, Lord Sainsbury of Turville has resigned as the minister responsible for this area. The timing of the move, ostensibly to dedicate himself to his business and charitable activities, has been met with much speculation in commercial and parliamentary circles. Dr Simon Best, chairman of the BioIndustry Association (BIA), appraised his tenure as "integral to the much-improved position of science and bioscience in this country", while noting his contribution to the science and innovation strategy review. He will continue to advise the government on a part-time basis on how UK companies can better harness innovation, Clinica understands. Malcolm Wicks (formerly energy) becomes responsible for science, which has a budget of £3.4bn ($6.5bn).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT053499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel